PT - JOURNAL ARTICLE AU - Yadav, Prashasti AU - Roychowdhury, Saileyee AU - Mukherjee, Nilanjan AU - Mukherjee, Reema AU - Roy, Sudipta Kumar AU - Bhattacharjee, Soumen AU - Das, Parimal TI - Identification of Novel Gene variants for Autism Spectrum Disorder in an Indian Patient using Whole Exome Sequencing AID - 10.1101/2024.02.28.24303417 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.28.24303417 4099 - http://medrxiv.org/content/early/2024/03/02/2024.02.28.24303417.short 4100 - http://medrxiv.org/content/early/2024/03/02/2024.02.28.24303417.full AB - Background Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction, along with restricted and repetitive behaviour patterns, interests or activities. Its prevalence has risen over the past few years, being four times more common in boys than girls. The cause of ASD is unclear, its etiology involves genetic, environmental, and gene-environment interactions. While past studies highlighted clinical genetic risks, genetic complexity of ASD, with variants of diverse frequencies, type, and inheritance patterns, requires further exploration for better management of disease. Researches have shown that the whole exome sequencing can be used to identify genetic variants associated with genetically heterogeneous conditions. The purpose of this study is to identify genetic variants by employing whole exome sequencing in an Indian ASD patient.Methods A female patient of age within 0-5 years, having characteristic features like hyperactivity and language impairment, was investigated and diagnosed using DSM-5 criteria. Peripheral blood sample collection was done followed by DNA extraction and whole exome sequencing. Variants analysis, identification and annotation were done using bioinformatics tools and databases. Identified pathogenic variants were reconfirmed by Sanger sequencing.Results and conclusion Our study uncover four genetic variations, comprising three missense variations in KIF1A (c.3839C>T), SETD5 (c.314A>C), MAPK81P3 (c.2849C>T), and one-stop gain variation in ERMARD (c.1523G>A). The ERMARD stop gain variation, predicted to induce nonsense-mediated decay, alter normal protein function through truncation and classified as likely pathogenic based on the ACMG guidelines and current available scientific evidence. In conclusion, we identified a likely pathogenic variant in ERMARD along with three missense variants in KIF1A, SETD5 and MAPK81P3 respectively. These findings suggest the potential contribution of ERMARD mutations to ASD susceptibility, emphasizing the need for further validation through functional studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe first author acknowledges Indian Council of Medical Research, India For providing Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee Institute of Science Banaras Hindu University Varanasi-221005, INDIA (Ref No: I.Sc./ECM-XVI/2023-2024/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript